159 related articles for article (PubMed ID: 21520162)
1. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥ 12)-core prostate biopsy.
Hong SK; Oh JJ; Byun SS; Hwang SI; Lee HJ; Choe G; Lee SE
Prostate; 2012 Jan; 72(1):51-7. PubMed ID: 21520162
[TBL] [Abstract][Full Text] [Related]
2. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer.
Kang J; Chen MH; Zhang Y; Moran BJ; Dosoretz DE; Katin MJ; Braccioforte MH; Salenius SA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e463-7. PubMed ID: 21944463
[TBL] [Abstract][Full Text] [Related]
3. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL.
Fukushima H; Masuda H; Kawakami S; Ito M; Sakura M; Numao N; Koga F; Saito K; Fujii Y; Yamamoto S; Yonese J; Fukui I; Kihara K
Urology; 2012 Jun; 79(6):1329-34. PubMed ID: 22656412
[TBL] [Abstract][Full Text] [Related]
4. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series.
Moreira DM; Anderson T; Gerber L; Thomas JA; Bañez LL; McKeever MG; Hoyo C; Grant D; Jayachandran J; Freedland SJ
Cancer Causes Control; 2011 Jul; 22(7):977-83. PubMed ID: 21562753
[TBL] [Abstract][Full Text] [Related]
5. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis.
De Nunzio C; Freedland SJ; Miano L; Finazzi Agrò E; Bañez L; Tubaro A
Eur J Surg Oncol; 2011 Dec; 37(12):1025-9. PubMed ID: 21963050
[TBL] [Abstract][Full Text] [Related]
6. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
7. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
8. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
[TBL] [Abstract][Full Text] [Related]
9. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
Inahara M; Suzuki H; Kojima S; Komiya A; Fukasawa S; Imamoto T; Naya Y; Ichikawa T
Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359
[TBL] [Abstract][Full Text] [Related]
10. Lowering the PSA threshold for prostate biopsy from 4 to 2.5 ng/ml: influence on cancer characteristics and number of men needed to biopt.
Müntener M; Kunz U; Eichler K; Puhan M; Schmid DM; Sulser T; Strebel RT
Urol Int; 2010; 84(2):141-6. PubMed ID: 20215816
[TBL] [Abstract][Full Text] [Related]
11. Reassessing the diagnostic yield of saturation biopsy of the prostate.
Ashley RA; Inman BA; Routh JC; Mynderse LA; Gettman MT; Blute ML
Eur Urol; 2008 May; 53(5):976-81. PubMed ID: 17997028
[TBL] [Abstract][Full Text] [Related]
12. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation.
Pepe P; Aragona F
Urology; 2007 Dec; 70(6):1131-5. PubMed ID: 18158033
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
14. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.
Scattoni V; Raber M; Abdollah F; Roscigno M; Dehò F; Angiolilli D; Maccagnano C; Gallina A; Capitanio U; Freschi M; Doglioni C; Rigatti P; Montorsi F
Eur Urol; 2010 Jan; 57(1):1-8. PubMed ID: 19720449
[TBL] [Abstract][Full Text] [Related]
15. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
16. Low risk patients benefit from extreme anterior apical sampling on initial biopsy for prostate cancer diagnosis.
Elshafei A; Kartha G; Li Y; S Moussa A; Hatem A; Gao T; Jones JS
Prostate; 2014 Sep; 74(12):1183-8. PubMed ID: 24962004
[TBL] [Abstract][Full Text] [Related]
17. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy.
Albisinni S; De Nunzio C; Tubaro A; Barry WT; Banez LL; Freedland SJ
Urology; 2012 Jul; 80(1):162-7. PubMed ID: 22608797
[TBL] [Abstract][Full Text] [Related]
18. The association of diabetes and positive prostate biopsy in a US veteran population.
Moses KA; Utuama OA; Goodman M; Issa MM
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):70-4. PubMed ID: 21894176
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and prostate cancer risk in the REDUCE trial.
Wu C; Moreira DM; Gerber L; Rittmaster RS; Andriole GL; Freedland SJ
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):326-31. PubMed ID: 21709690
[TBL] [Abstract][Full Text] [Related]
20. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study.
De Nunzio C; Albisinni S; Freedland SJ; Miano L; Cindolo L; Finazzi Agrò E; Autorino R; De Sio M; Schips L; Tubaro A
Urol Oncol; 2013 Oct; 31(7):997-1002. PubMed ID: 21925906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
